肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCO：Trifluridine/Tipiracil治疗亚洲人群转移性结直肠癌

2017-12-08 MedSci MedSci原创

转移性结直肠癌亚洲人群Trifluridine/Tipiracil
关注

Trifluridine/Tipiracil（TAS-102）在一项日本的Ⅱ期临床试验中已证明对转移性结直肠癌患者有效。JCO近期报道了Trifluridine/Tipiracil在生物治疗暴露或未暴露的亚洲转移性结直肠癌患者中的有效性及安全性。

Trifluridine/Tipiracil（TAS-102）在一项日本的Ⅱ期临床试验中已证明对转移性结直肠癌患者有效。JCO近期报道了Trifluridine/Tipiracil在生物治疗暴露或未暴露的亚洲转移性结直肠癌患者中的有效性及安全性。该RCT试验包括中国、韩国、泰国共30个中心。患者年龄≥18岁，病理确诊结直肠腺癌，已知KRAS状态且之前接受过2个以上的化疗方案治疗后复发或耐药。符合入组条件的患者随机（2：1）分为Trifluridine/Tipiracil组（每天两次口服；两周内服药5天，间隔2天，周期间14天间隔）或对照组。主要的研究终点为总生存情况。在2013年10月16日至2015年6月15日，共纳入406例患者，其中治疗组271例，对照组135例。与对照组相比，治疗组死亡风险显着下降。治疗组平均总生存时间更长（7.8个月vs7.1个月），平均随访时间为13.8个月和13.4个月。两组间严重不良反应情况相似。未出现治疗相关死亡。文章最后认为，在标准化疗方案耐药或复发的亚洲转移性结直肠癌患中，与安慰剂组相比，Trifluridine/Tipiracil方案可以显着改善

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2018-03-03 liao1630

    #Trifluridine/Tipiracil#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2018-04-03 lidong40

    #JCO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-10 1249842em09(暂无昵称)

    #转移性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-10 crystal0564

    #结直肠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-10 docwu2019

    #亚洲人群#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1715742, encodeId=7f6e1e15742d5, content=<a href='/topic/show?id=95461e8156e' target=_blank style='color:#2F92EE;'>#Trifluridine/Tipiracil#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17815, encryptionId=95461e8156e, topicName=Trifluridine/Tipiracil)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c56b32012627, createdName=liao1630, createdTime=Sat Mar 03 05:11:00 CST 2018, time=2018-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891467, encodeId=c034189146ea0, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Tue Apr 03 06:11:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386320, encodeId=cb92138632040, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453038, encodeId=15bc1453038fd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619866, encodeId=531f161986695, content=<a href='/topic/show?id=1f652426921' target=_blank style='color:#2F92EE;'>#亚洲人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24269, encryptionId=1f652426921, topicName=亚洲人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 10 01:11:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267806, encodeId=dea926e806ab, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Fri Dec 08 12:21:44 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-08 139****5926

    好好文章学习了

    0

相关资讯

CLIN CANCER RES：循环肿瘤DNA早期改变可以作为转移性结直肠癌患者治疗效果的标志

转移性结直肠癌患者化疗有效性的标志对最佳治疗方案的选择至关重要。CLIN CANCER RES近期发表了一篇文章，研究循环肿瘤DNA（ctDNA）早期改变作为治疗效果的分子标志的可行性。研究纳入的患者为接受一线或二线化疗的转移性结直肠癌患者。在第1个（C0），第2个（C1）和/或第3个（C2）化疗周期前收集血清评估循环肿瘤DNA情况，使用PCR检测基因突变（KRAS、BRAF、TP53）或超甲基化

CLIN CANCER RES：低剂量环磷酰胺诱导抗肿瘤T细胞反应且与转移性结直肠癌患者预后有关

抗肿瘤T细胞反应可以控制肿瘤，但是免疫抑制机制会影响其功能。Treg细胞在转移性结直肠癌中发挥的作用尚未知。之前有研究证明Treg缺失可以增强结直肠癌特异性效应T细胞反应。在动物模型及人体试验中证实低剂量环磷酰胺可以靶向Treg，但是环磷酰胺对转移性结直肠癌的影响尚不清楚。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌

在治疗严重的转移性结直肠癌的患者中，与安慰剂相比，TAS-102——曲氟尿苷和盐酸盐复方药物具有显着的总体生存效益。在临床前模型中，TAS-102+贝伐单抗，与单独使用二者任何一个药物相比，其在对抗结肠直肠癌异种移植的活性中表现出了增强。近日，在医学杂志Lancet Oncol上面发表了一篇研究文章，该文章旨在评估TAS-102+贝伐单抗的活性和安全性。

必看：肠癌大咖共话转移性结直肠癌靶向治疗热点

2017年10月27-29日，第二届中国抗癌协会肿瘤靶向治疗专业委员会年会在湖北武汉成功召开，肿瘤靶向治疗开展得如火如荼，其进展日新月异，本次大会特别邀请国内著名的肿瘤学基础和临床专家就相关领域最新进展进行精彩的专题报告，深入探讨前沿理论和热点问题。肿瘤资讯有幸邀请到张克亮、袁瑛、曾珊、张涛、殷先利、刘莺等教授，就转移性结直肠癌整体治疗策略及靶向治疗相关热点问题进行点评。

ANN ONCOL：MAPK信号通路基因改变对接受一线FOLFIRI联合贝伐单抗治疗的转移性结直肠癌患者预后的影响

MAPK酶1（MKNK1）位于RAS/RAF/ERK和MAP3K1/MKK/p38信号通路的下游。磷酸化MKNK1调节翻译起始因子4E的功能。翻译起始因子4E是转录控制的关键因素，其表达在转移性结直肠癌患者中升高。临床前数据表明MKNK1上调血管生成因子促进血管生成。ANN ONCOL近期发表了一篇文章，研究MKNK1基因改变是否可以预测接受一线FOLFIRI和贝伐单抗治疗的转移性结直肠癌患者的预

JAMA Oncol：抗肿瘤疫苗5T4联用环磷酰胺治疗转移性结直肠癌

研究认为改良安卡拉痘苗-5T4联用低剂量的环磷酰胺可有效延长转移性结直肠癌患者生存期